Anuncia Medical Successfully Launches Second Generation Device to Treat Hydrocephalus at Several Leading Neurosurgical Centers Across the United States.
QurAlis
March 9, 2023
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
QurAlis
January 5, 2023
QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
Portfolio News
2022
QurAlis
December 8, 2022
QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
Anuncia Medical, Inc.
September 29, 2022
Anuncia Medical, Inc., receives FDA clearance for the ReFlow® System Mini for the treatment of patients with hydrocephalus
GreenLight Biosciences
August 12, 2022
GreenLight Biosciences announces $109 million financing
Portfolio News
2021
Biopharmaceutical Research Company
November 9, 2021
Biopharmaceutical Research Company Partners with Vanguard Scientific on Technology
Integration for Cannabis Extraction
Biopharmaceutical Research Company
May 14, 2021
Marijuana Research Growers Receive U.S. Approval
Anunia Medical, Inc.
May 4, 2021
Anuncia ReFlow™ Tech
Honored With Fast
Company 2021 World
Changing Ideas Awards
Anuncia Medical, Inc.
March 2, 2021
Anuncia Inc. Receives
FDA "Breakthrough
Device Designation" for
ReFlow™ System Mini
Continuus Pharmaceuticals
January 21, 2021
Continuus Pharmaceuticals Secures $69.3 Million Government Contract to Manufacture Critical Medicines in the U.S.
2020
Onc.ai
December 3, 2020
Onc.AI raises $6M Financing Round co-led by Blue Venture Fund and Accomplice
Aquacultural Research Corp
August 10, 2020
On the Shores of Cape Cod, Where the Oyster Is Their World
RefleXion Medical
July 8, 2020
Reflexion and Telix Pharmaceuticals Announce Strategic Collaboration For Treatment Of High-Risk Cancers
Greenlight Biosciences
June 16, 2020
GreenLight Supercharges Efforts with $102M in Funding
RefleXion Medical
May 28, 2020
RefleXion Announces Clinical Collaboration to Evaluate Biology-guided Radiotherapy With Merck’s KEYTRUDA® for Certain Late-Stage Cancers
QurAlis
May 13, 2020
QurAlis Hauls In $42M to Move New ALS Therapies Into Human Testing
Greenlight Biosciences
May 12, 2020
$17M Raised for COVID-19 Vaccine Manufacturing
EnClear Therapies
February 19, 2020
EnClear Therapies Announces $10M Series A Financing